MRK.XETRA

Merck KGaA

MRK.XETRA, Germany

Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography resins, single-use systems, process chemicals, and excipients; and life science services, such as monoclonal antibodies, high-potency active pharmaceutical ingredients, antibody-drug conjugates, and viral and gene therapy products, as well as contract development, manufacturing, and testing services. Its Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, cardiovascular, metabolism, and endocrinology disorders; and provides general medicines, injection devices, and disease monitoring software. The Electronics segment supplies materials comprising thin films, patterning and planarization formulations, specialty gases, optronics, and optical metrology equipment for the semiconductor and display industries, as well as provides delivery systems and services. It has in-licensing agreements with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

https://www.emdgroup.com

Stock Price

€0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MRK.XETRA
stock
MRK.XETRA

Kepler Cheuvreux Unveils "Top 10" German Stock Picks for 2026 Amidst Economic Inflection Point FinancialContent

Read more →
MRK.XETRA
stock
MRK.XETRA

Merck to acquire Cidara Therapeutics for $9.2B Proactive financial news

Read more →

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

2

Buy

10

Hold

3

Sell

1

Strong Sell

1

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

17.92

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Medium

1.93

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

3.12 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.77 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

19.88 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Low

0.76

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Merck KGaA

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.84

Latest Release

Date

2025-09-30

EPS Actual

2.07

EPS Estimate

2.44

EPS Difference

-0.37

Surprise Percent

-15.1639%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.3)
GARP
Fair GARP(6)
Growth
Moderate Growth(5)
Momentum
Moderate Momentum(4.5)
Net Net
Possible Net-Net(4)
Quality
High Quality(7)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

€ 0

Short Term Investments

€ 0

Receivables

€ 0

Inventories

€ 0

Total Current Assets

€ 0

Property Plant Equipment

€ 0

Total Assets

€ 0

Payables

€ 0

Short Term Debt

€ 0

Long Term Debt

€ 0

Total Liabilities

€ 0

Equity

€ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

€ 0

Depreciation

€ 0

Change In Working Capital

€ 0

Cash From Operations

€ 0

Capital Expenditures

€ 0

Cash From Investing

€ 0

Cash From Financing

€ 0

Net Change In Cash

€ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.